Therapeutic Trials Actively Recruiting: Pancreatic Ductal Adenocarcinoma
| Name | NCT # | Contact |
|---|---|---|
| A Phase III Trial of Perioperative versus Adjuvant Chemotherapy for Resectable Pancreatic Cancer | NCT04340141 | Amy Zeng (415) 215-6489 [email protected] |
| A Phase 1 Dose Escalation and Expanded Cohort Study of P-MUC1C-ALLO1 in adult subjects With Advanced or Metastatic Solid Tumors | NCT05239143 | Sarah Darmstadt (415) 307-7863 [email protected] |
| Phase II/III Second-Line NABPLAGEM vs. Nab-Paclitaxel/Gemcitabine in BRCA1/2 or PALB2 Mutant Metastatic Pancreatic | NCT06115499 | Amy Zeng (415) 215-6489 [email protected] |
| Phase II study of hypofractionated radiation therapy to Augment immune Response in patients with Metastatic GastroIntestinal malignancies progressing on immune therapy | NCT04221893 |
Luchia Andemicael |
| A Phase 1b/2, Dose-escalation, Randomized, Multicenter Study of Maintenance Ivaltinostat plus Capecitabine or Capecitabine Monotherapy in Patients with Metastatic Pancreatic Adenocarcinoma Whose Disease Has Not Progressed on First Line FOLFIRINOX Chemotherapy | NCT05249101 | Evelyn Montenegro (415) 218-8398 [email protected] |
| Pilot Study of Ketamine-Assisted Talk Therapy for Demoralization in Patients with Pancreatic Ductal Adenocarcinoma and Pain | NCT06077487 | Zoe Lopez Meraz [email protected] |
| A Phase II, Open-Label, Multicenter, Randomized Study of the Efficacy and Safety of Adjuvant Autogene Cevumeran Plus Atezolizumab and mFOLFIRINOX versus mFOLFIRINOX Alone in Patients with Resected Pancreatic Ductal Adenocarcinoma | NCT05968326 | Insiyah Merchant (415) 205-8117 [email protected] |
Non-Therapeutic Trials
| Name | NCT # | Contact |
|---|---|---|
| The Pancreatic Cancer Early Detection Consortium (PRECEDE) | NCT04970056 | Gorang Gupta (415) 476-2874 [email protected] |
| Lifestyle and Outcomes after Gastrointestinal Cancer: A Prospective Cohort Study | N/A | Amy Zeng (415) 215-6489 [email protected] |